Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Unraveling the mechanistic links between blood pressure regulation and calcium-magnesium homeostasis: Insights into hypertension, hyperparathyroidism, and mineral disorders

  • Pritha Dutta,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing

    Affiliation Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada

    ⨯
  • Anita T. Layton

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – review & editing

    anita.layton@uwaterloo.ca

    Affiliation Departments of Applied Mathematics and Biology, School of Pharmacy, Cheriton School of Computer Science, University of Waterloo, Waterloo, Ontario, Canada

    ⨯

Abstract

The systems regulating blood pressure and calcium-magnesium (Ca2+-Mg2+) homeostasis are increasingly recognized to have clinically relevant interactions, where alterations in one can lead to significant changes in the other. In this study, we developed a computational model integrating blood pressure regulation and Ca2+-Mg2+ homeostasis in a male rat. We simulated various conditions, including hypertension, Ca2+, Mg2+, and vitamin D3 deficiencies, and primary hyperparathyroidism. Simulations of hypertension, induced by various stimuli like increased renin or aldosterone secretion, demonstrated significant effects on parathyroid hormone (PTH), calcitriol, renal Ca2+/Mg2+ handling, and bone resorption. Dietary Ca2+, Mg2+, and vitamin D3 deficiencies was predicted to elevate mean arterial pressure, with Mg2+ deficiency having a stronger effect. Furthermore, the model predicted that primary hyperparathyroidism elevates PTH, Ca2+, and calcitriol, leading to increased mean arterial pressure and bone loss. Overall, this model provides valuable insights into the mechanistic links between blood pressure regulation and Ca2+-Mg2+ homeostasis, offering insights into clinical conditions like hypertension and hyperparathyroidism.

Citation: Dutta P, Layton AT (2026) Unraveling the mechanistic links between blood pressure regulation and calcium-magnesium homeostasis: Insights into hypertension, hyperparathyroidism, and mineral disorders. PLoS One 21(2): e0341800. https://doi.org/10.1371/journal.pone.0341800

Editor: Toshio Matsumoto, Tokushima University, JAPAN

Received: December 2, 2025; Accepted: January 12, 2026; Published: February 4, 2026

Copyright: © 2026 Dutta, Layton. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: Data are available at https://github.com/Pritha17/Blood-pressure-and-calcium-magnesium-homeostasis-regulation.

Funding: This research was supported in part by the Natural Sciences and Engineering Research Council of Canada, via a Discovery award RGPIN-2025-03958 to AT Layton. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Hypertension is the leading cause of cardiovascular disease worldwide [1], and its prevalence has been rising in recent years due to factors such as an aging population and lifestyle changes, including decreased physical activity and the widespread consumption of Western diets [2]. Furthermore, a significant portion of the global population fails to meet the recommended dietary intake of magnesium (Mg2+) and calcium (Ca2+) [3,4]. For example, the standard diet in the United States provides only about 50% of the recommended daily intake of Mg2+ [5], and the 2017-2018 National Health and Nutrition Examination Survey found that nearly half of the United States population did not meet their estimated average requirements for Ca2+ [6]. Additionally, approximately 100,000 people in the United States each year are diagnosed with primary hyperparathyroidism [7], which involves elevated blood Ca2+ and its regulatory hormone parathyroid hormone (PTH) levels. Given these factors, it is essential to understand how blood pressure regulation and Ca2+-Mg2+ homeostasis are affected by these conditions.

The systems regulating blood pressure and Ca2+-Mg2+ homeostasis are increasingly recognized to have significant and clinically relevant interactions [8–10]. A key component of blood pressure regulation is the renin-angiotensin-aldosterone system (RAAS). The RAAS is a hormonal system that regulates fluid balance and blood pressure through a cascade of reactions. One of the end products angiotensin II (Ang II) promotes vascular constriction and stimulates the adrenal glands to release aldosterone, which enhances sodium (Na+) and water retention by the kidneys, ultimately increasing blood volume and pressure. Ca2+, Mg2+, and their regulatory hormones, PTH and calcitriol (1,25(OH)2D3; active form of vitamin D3), play a crucial role in regulating various elements of the RAAS [8–10]. For instance, Ca2+ and calcitriol influence renin secretion from the juxtaglomerular (JG) cells in the kidneys [11–14]. Additionally, Ca2+, Mg2+, and PTH regulate aldosterone secretion from the adrenal gland [15–19] as well as vascular resistance [20–22]. Both aldosterone and Ang II also influence PTH secretion from the parathyroid gland [23]. Furthermore, PTH and Ca2+ control Na+ reabsorption of the kidney, specifically, along the proximal tubule and thick ascending limb segments of the nephron [24,25]; Na+ reabsorption in turn affects the reabsorption of Ca2+ and Mg2+ in these nephron segments. Ang II and aldosterone also indirectly influence Ca2+ and Mg2+ reabsorption in the kidneys by regulating Na+ reabsorption. Finally, Ca2+ and Mg2+ have opposing effects on renal sympathetic nervous activity (RSNA) [26,27], which modulates renin secretion and renal Na+ transport. This complex network of interconnections between the two systems is illustrated by the brown arrows in Fig 1. As a result of these couplings and feedbacks, dysregulation in one system can significantly impact the other. Therefore, understanding the interactions between these systems is increasingly important for accurately assessing their impact on health.

thumbnail
Download:
Fig 1. Schematic representation of the interactions between the blood pressure and Ca2+-Mg2+ homeostasis models.

Mauve nodes, plasma [Ca2+], [Mg2+], [1,25(OH)2D3], and [PTH]; yellow nodes, renal Na+, Ca2+, and Mg2+ handling; blue nodes, renin-angiotensin-aldosterone system. (Node colors match those in Fig 2.) Solid arrows indicate activation and dotted arrows indicate inhibition. Brown arrows indicate the direct links between components of the blood pressure regulation model and the Ca2+-Mg2+ homeostasis model. In this schematic, distal tubule includes the distal convoluted tubule, connecting tubule, and collecting duct. ACE, angiotensin-converting enzyme; AGT, angiotensinogen; ALD, aldosterone; Ang I, angiotensin I; Ang II, angiotensin II; AT1R-bound Ang II, angiotensin II type 1 receptor-bound angiotensin II; AT2R-bound Ang II, angiotensin II type 2 receptor-bound angiotensin II; PRC, plasma renin concentration.

https://doi.org/10.1371/journal.pone.0341800.g001

Mechanistic modeling provides a comprehensive framework for understanding and analyzing complex physiological systems. In this study, we integrated our previously developed Ca2+-Mg2+ homeostasis model [28] with a blood pressure regulation model [29], both formulated for the male rat, to quantify the interactions between these two systems. This integrated model was then used to simulate various conditions, including hypertension, Ca2+, Mg2+, and vitamin D deficiencies, and primary hyperparathyroidism.

Materials and methods

As noted above, the present model integrates our previously developed model of Ca2+ and Mg2+ homeostasis [28] with a blood pressure regulation model [29]. The blood pressure regulation model describes, using a large system of coupled nonlinear algebraic differential equations, the interactions among physiological systems key to this process: the cardiovascular system, the renal system, the renal sympathetic nervous system, and the RAAS. The latter three regulate blood pressure via their effects on vascular resistance and on electrolyte and fluid balance. A schematic diagram is shown in Fig 2A. Model equations and parameter values can be found in Ref. [29].

thumbnail
Download:
Fig 2. Schematic diagram of the integrative model.

(A) Blood pressure regulation model. Pink nodes denote variables that describe cardiovascular function; green nodes, renal hemodynamics; yellow nodes, renal Na+ and fluid handling; blue nodes, the renin-angiotensin-aldosterone system (RAAS). Solid arrows indicate activation and dotted arrows indicate inhibition. In this schematic, the proximal tubule includes also the loop of Henle. (B) Ca2+-Mg2+ homeostasis model. The model consists of five compartments: plasma, intestine, kidney, parathyroid gland, and bone. Solid arrows with open arrowheads indicate fluxes, solid arrows with closed arrowheads indicate activation, and dotted arrows indicate inhibition. All arrows are color coded. Green arrows, Ca2+; red arrows, Mg2+, blue arrows, parathyroid hormone (PTH); purple arrows, 1,25(OH)2D3. ACE, angiotensin-converting enzyme; AGT, angiotensinogen; ALD, aldosterone; Ang I, angiotensin I; Ang II, angiotensin II; AT1R-bound Ang II, angiotensin II type 1 receptor-bound angiotensin II; AT2R-bound Ang II, angiotensin II type 2 receptor-bound angiotensin II; PRC, plasma renin concentration.

https://doi.org/10.1371/journal.pone.0341800.g002

The Ca2+ and Mg2+ homeostasis model consists of five compartments: plasma, parathyroid gland, intestine, kidney, and bone. The model describes, using a large system of coupled nonlinear ordinary differential equations, the exchanges of Ca2+, Mg2+, PTH, and calcitriol among these compartments. These exchanges together determine plasma [Ca2+] and [Mg2+], which are kept within physiological ranges by means of feedback controls. A schematic diagram is shown in Fig 2B. Model equations and parameter values can be found in Ref. [28].

In the following sections we define the equations for the regulation of different components of the blood pressure regulation model by Ca2+, Mg2+, PTH, and 1,25(OH)2D3 and vice-versa. As previously noted, the interactions between the two systems are summarized in Fig 1. New parameters that characterize these interactions are listed in Table 1.

thumbnail
Download:
Table 1. Descriptions and values of new model parameters and variables at baseline for a male rat.

https://doi.org/10.1371/journal.pone.0341800.t001

RAAS: Renin secretion

We begin with the RAAS, which as noted above is a key hormonal system that regulates fluid balance, primarily via its actions on the kidney, and vascular tone through a series of biochemical reactions. The reaction cascade “begins" with renin, which is secreted by the JG cells in the kidneys. Renin secretion is given by

(1)

where represents normalized renin secretion, and , , , , and represent the effect of tubular Na+ flow past the macula densa, RSNA, Ang II receptor type 1 (AT1R)-bound Ang II concentration, plasma Ca2+ ([Ca), and plasma 1,25(OH)2D3 concentration ([1,25(OH)2D3]p) on renin secretion rate. All these terms are equal to 1 in the baseline condition. For definitions of Nrs, , , and refer to Ref. [29]. The terms , and are introduced in this study and defined below.

Although Ca2+ does not directly regulate renin secretion, when plasma Ca2+ concentration is elevated, cAMP-stimulated renin secretion is inhibited, and vice versa (see dashed brown arrow between the plasma [Ca2+] and PRC nodes in Fig 1). Acute hypercalcemia suppresses plasma renin activity (PRA) by acting on the calcium-sensing receptor (CaSR) [11]. The JG cells, which express CaSR, reduce renin secretion when the receptor is activated [12]. The basolateral surface of the JG cells is exposed to the renal cortical interstitium, so elevated Ca2+ levels in this area could directly stimulate the CaSR on JG cells, leading to a reduction in renin secretion. The effect of Ca2+ on renin secretion is given by

(2)

where represents the sensitivity of renin secretion to plasma [Ca2+].

Renin secretion increases significantly in the presence of 1,25(OH)2D3 deficiency as well as toxicity. Zhou et al. reported a 1.5-fold increase in PRA in 1α-hydroxylase knockout mice compared to control [13]. Treatment of 1α-hydroxylase knockout mice with 1,25(OH)2D3 led to the normalization of PRA [13]. Thus, 1,25(OH)2D3 deficiency leads to upregulation of renin secretion. In addition, administration of high doses of calcitriol to male rats increased PRA by ∼2.5-fold [14]. Thus, sufficiently high levels of 1,25(OH)2D3 also upregulates renin secretion.

We defined such that (i) when [1,25(OH)2D3]p is within the range of 80-170 pM, , (ii) when [1,25(OH)2D3]p is less than 80 pM, gradually increases to a maximum of 1.5-fold as [1,25(OH)2D3]p approaches zero, and (iii) when [1,25(OH)2D3]p is greater than 170 pM, gradually increases to a maximum of 2-fold. Thus, the effect of 1,25(OH)2D3 on renin secretion is given by

(3)

where

(4)(5)(6)

The parameters and represent the sensitivity of renin secretion to low and high [1,25(OH)2 D3]p, respectively.

RAAS: Aldosterone secretion

Aldosterone is the end product of the RAAS reaction cascade. It elevates blood pressure via its Na+ retention effect on the kidneys. Normalized aldosterone secretion () is given by

(7)

ALD secretion is affected by the plasma K+ to Na+ ratio (), mean arterial pressure (), AT1R-bound Ang II (), Ca2+ (), Mg2+ (), and PTH (). All these terms are equal to 1 in the baseline condition. For definitions of , , , and refer to Ref. [29]. The terms , , and are defined below.

Findings in rat zona glomerulosa (ZG) cells [15] have suggested that extracellular Ca2+ level could serve as an independent stimulator of aldosterone secretion. That effect is modelled as

(8)

where represents the sensitivity of aldosterone secretion to plasma Ca2+ concentration.

Studies in cultured cell [16], rat [17], and human [30] have suggested that extracellular Mg2+ decreases sensitivity of adrenal glomerulosa cells to Ang II-stimulated aldosterone secretion. We model the effect of Mg2+ on aldosterone secretion as

(9)

where represents the sensitivity of aldosterone secretion to plasma Mg2+ concentration ([Mg).

PTH binds to PTH receptor and facilitates Ca2+ influx through the voltage-gated Ca2+ channels, thus increasing Ang II-stimulated aldosterone secretion [18,19,31,32]. That effect is modelled as

(10)

where represents the sensitivity of aldosterone secretion to [PTH]p.

Effect of angiotensin II and aldosterone on PTH secretion

Human parathyroid cells have been found to express mineralocorticoid receptors (MRs) [23,32] and AT1Rs [23]. The AT1R expression level was found to be ∼100-fold lower than the MR expression level [23]. Lenzini et al. reported that at physiological Ca2+ concentrations cells exposed to aldosterone increased PTH secretion by 271% compared to control [23]. This increase in PTH secretion was abolished on treatment with an MR blocker. In addition, at physiological Ca2+ concentrations cells exposed to Ang II increased PTH secretion by 267% and this increase was abolished on treatment with an AT1R antagonist [23]. However, co-stimulation with both aldosterone and Ang II did not produce any additive increase in PTH secretion, with PTH secretion increasing by 225% compared to control [23]. Based on these observations, we model the effect of aldosterone and Ang II on PTH secretion as

(11)

where

(12)(13)

In Eqs (12) and (13), [ALD]p denotes plasma aldosterone concentration and [AT1R] denotes AT1R-bound Ang II concentration. and characterize the sensitivity of PTH secretion to aldosterone and AT1R-bound Ang II, respectively.

The influence of RAAS on rates of change of parathyroid gland and plasma PTH concentrations (denoted [PTH]g and [PTH]p) is incorporated into the corresponding model equations in Ca2+-Mg2+ homeostasis model (equations 1 and 6 in Ref. [28]) via the term:

(14)(15)

The effects of AT1R, aldosterone, and plasma Ca2+ and Mg2+ on PTH are summarized in Fig 1. For descriptions and values of all parameters in the above two equations refer to Ref. [28] and table 2 therein.

Effect of calcium and magnesium on RSNA

RSNA constricts the afferent arteriole, promotes Na+ and water retention by the kidneys, and elevates blood pressure. These effects are incorporated into the model; see Ref. [33] for the vasoconstrictive effect and see below for the anti-natriuretic effect. The regulation of RSNA is given by

(16)

where represents the normalized RSNA, and , , , and represent the effect of mean arterial pressure (MAP), right atrial pressure (RAP), Ca2+, and Mg2+ on RSNA. All these terms are equal to 1 in the baseline condition. For definitions of and refer to Ref. [29] and and are defined below.

Ca2+ influx through N-type Ca2+ channels in sympathetic nerves increases RSNA, which raises the release of norepinephrine [26]. Mg2+ suppresses RSNA and norepinephrine release by blocking N-type Ca2+ channels in sympathetic nerves [27]. Thus, the balance between Ca2+ and Mg2+ is important for RSNA. We model the regulation of RSNA by Ca2+ and Mg2+ as

(17)(18)

where [Ca2+]p−eq and [Mg2+]p−eq denote the concentrations of plasma Ca2+ and Mg2+ at equilibrium, respectively.

Effect of angiotensin II on bone resorption

Approximately 99% of the total body Ca2+ is stored in the bones. Thus, to maintain calcium balance, it is crucial to regulate the exchange of calcium between the bones and blood. Bone resorption rate is defined as

(19)

where and denote the minimal and maximal resorption rates, respectively, and their values can be found in Table 2 of Ref. [28]. The Michaelis-Menten terms and represent the effect of PTH and 1,25(OH)2D3 on resorption, respectively [28]; low [1,25(OH)2D3]p suppresses the PTH-driven resorption, while physiologic or high levels “permit” it. The term represents the effect of AT1R-bound Ang II on bone resorption and is defined below.

Bones express AT1R, and Ang II binds to AT1R to activate osteoclasts through RANKL induction and hence promotes osteoporosis [34]. Treatment with AT1R blocker ameliorates osteoporosis [34]. We assume the following sigmoidal relation between bone resorption and AT1R-bound Ang II.

(20)

where denotes the sensitivity of bone resorption to AT1R-bound Ang II.

Sodium reabsorption in the proximal tubule and thick ascending limb

The kidneys play a crucial role in long-term blood pressure regulation by maintaining electrolyte and fluid homeostasis via urinary excretion. The proximal tubule and thick ascending limb are the two primary sites along the nephron for Na+ reabsorption. Fractional reabsorption of Na+ along these segments is given by

(21)

where and represent fractional Na+ reabsorption in the proximal tubule and thick ascending limb at equilibrium and are assumed to be 0.60 and 0.20, respectively. , , , , and denote the effect of PTH, CaSR, filtered Na+ load, AT1R-bound Ang II, and RSNA, respectively, on fractional Na+ reabsorption and are equal to 1 at baseline. The definitions of , , and can be found in Ref. [29] and and are defined below.

PTH inhibits Na+/H+ exchanger 3 (NHE3) in the proximal tubule and reduces proximal tubule Na+ reabsorption [24]. We model this effect by

(22)

where represents the sensitivity of proximal tubule Na+ reabsorption to plasma [PTH].

Ca2+ inhibits Na+–K+–Cl− cotransporter 2 (NKCC2) in the thick ascending limb through the CaSR and hence reduces Na+ reabsorption along this segment [25]. This effect is represented as

(23)

where represents the sensitivity of Na+ reabsorption in the thick ascending limb to plasma [Ca2+].

Effect of angiotensin II on arterial resistance

In vascular smooth muscle cells, Ang II binds to AT1R and increases intracellular Ca2+ both through Ca2+ influx from L-type Ca2+ channels and Ca2+ release from intracellular stores. Administration of angiotensin converting enzyme (ACE) inhibitor to spontaneously hypertensive rats reduced peripheral resistance by ∼40% [35] and Ang II infusion to male Wistar rats increased peripheral resistance by ∼140% [36]. Based on these observations, we model the effect of AT1R-bound Ang II on arterial resistance as

(24)

where [AT1R]eq denotes the concentration of AT1R-bound Ang II at equilibrium.

Effect of calcium, magnesium, and parathyroid hormone on vascular resistance

Increased Ca2+ influx into vascular smooth muscle cells increases vascular resistance. Low and high Ca2+ supplementation in male Sprague-Dawley rats decreased and increased vascular resistance by 13.5% and 7%, respectively [20]. Accordingly, we model the effect of plasma Ca2+ on vascular resistance as

(25)

where [Ca2+]p-eq denotes the concentration of plasma Ca2+ at equilibrium.

Mg2+ causes vasodilation of vascular smooth muscle cells by blocking Ca2+ influx through L-type Ca2+ channels. High extracellular Mg2+ reduced myogenic tone in wild-type male mice [21]. We model the effect of plasma Mg2+ on vascular resistance as

(26)

where [Mg2+]p-eq denotes the concentration of plasma Mg2+ at equilibrium.

PTH activates PTH receptor 1 on vascular smooth muscle cells, preferentially engaging Gs-coupled G protein → cyclic adenosine monophosphate (cAMP) → protein kinase A (PKA) signaling while weakly stimulating Ca2+ mobilization [22]. The net effect is reduced myosin light-chain phosphorylation and smooth muscle relaxation [37]. We modeled the effect of PTH on vascular resistance by assuming that at very low PTH vascular resistance would increase by 20% and at high PTH vascular resistance would decrease by 20%.

(27)

where [PTH]p-eq denotes the concentration of plasma PTH at equilibrium.

The regulation of arterial resistance is given by

(28)

where denotes the basic arterial resistance and denotes the autonomic multiplier effect and their definitions can be found in Ref. [29]. The parameters , , , and denote the effect of [AT1R-bound Ang II], [Ca2+], [Mg2+], and [PTH] on vascular resistance and are defined in Eqs (25)–(28).

The regulation of afferent arteriolar resistance is defined as

(29)

where denotes the afferent arteriolar resistance at equilibrium. The parameters , , , , and denote the effect of RSNA, tubuloglomerular feedback (TGF) signal, myogenic response [38], [AT1R-bound Ang II], and [AT2R-bound Ang II] on afferent arteriolar resistance, respectively, and their definitions can be found in Ref. [29]. The parameters , , and denote the effect of [Ca2+], [Mg2+], and [PTH] on afferent arteriolar resistance and are defined in Eqs (26)–(28).

Simulating hypertension

Hypertension is a multifactorial disease that may involve a variety of triggers, including overactive RSNA, RAAS, or arterial stiffening. The model parameters adjusted to simulate hypertensive stimuli are the equilibrium values for RSNA, renin secretion rate, aldosterone secretion rate, and afferent arteriole resistance. We consider five hypertensive cases, featuring primarily an overactive RSNA, increased renin secretion, increased aldosterone secretion, increased vascular tone, or a combination of these stimuli. These models are referred to as HTN-RSNA, HTN-Renin, HTN-ALD, HTN-AA, and HTN-Combined, respectively. For each hypertensive case, parameters were adjusted so that the MAP predicted for the hypertensive model is approximately 120 mmHg. These parameter sets are shown in Table 2.

thumbnail
Download:
Table 2. Changes in model parameters to simulate five model instances of hypertension, each with different primary trigger(s), labelled RSNA, Renin, ALD, AA, and Combined. RSNA, renal sympathetic nervous activity; ALD, aldosterone; AA, afferent arterial.

https://doi.org/10.1371/journal.pone.0341800.t002

Results

Sensitivity analysis

We performed a local sensitivity analysis by varying each model parameter by ±5% and computing the corresponding steady state. The percentage changes in RSNA, glomerular filtration rate (GFR), MAP, aldosterone concentration, PRA, [PTH], [1,25(OH)2D3], [Mg2+], and [Ca2+] corresponding to 5% increase in parameter values are shown in Fig 3. Results obtained by decreasing parameters by 5% exhibit similar trends (not shown).

thumbnail
Download:
Fig 3. Local sensitivity analysis.

Conducted by increasing individual parameters by 5%. The resulting percent change in model steady state concentrations from baseline is presented here. White indicates the resulting change was less than 1%. RSNA, renal sympathetic nervous activity; GFR, glomerular filtration rate; MAP, mean arterial pressure; [ALD], plasma aldosterone concentration; PRA, plasma renin activity; [PTH], plasma PTH concentration; [1,25(OH)2D3], plasma 1,25(OH)2D3 concentration; [Mg2+], plasma Mg2+ concentration; [Ca2+], plasma Ca2+ concentration.

https://doi.org/10.1371/journal.pone.0341800.g003

Changes in parameters that regulate renal Na+ transport have the largest impact on blood pressure-related variables. Specifically, results in Fig 3 indicate that a 5% increase in the fractional reabsorption rates of Na+ in the proximal tubule and thick ascending limb (), distal tubule (), and collecting duct () causes significant change in aldosterone concentration. Additionally, has significant impact on GFR (since it determines the macula densa Na+ flow), RSNA, and MAP (by regulating water reabsorption and consequently extracellular fluid volume).

As expected, Ca2+-Mg2+-related variables are sensitive to changes in (some) parameters that characterize renal Ca2+ and Mg2+ transport. A 5% increase in minimal thick ascending limb fractional Mg2+ reabsorption () causes a significant change in plasma [PTH], [1,25(OH)2D3], [Mg2+], and [Ca2+]. For instance, the increase in significantly elevates plasma [Mg2+] and [Ca2+], while suppressing plasma [PTH]. This occurs because increased plasma [Mg2+] directly stimulates 1,25(OH)2D3 production, which in turn enhances intestinal Ca2+ absorption, thereby increasing plasma [Ca2+]. Consequently, [PTH] decreases due to inhibition from both increased [1,25(OH)2D3] and elevated [Mg2+] and [Ca2+]. In contrast, a similar change in fractional Ca2+ reabsorption in the proximal tubule () has minimal impact on these variables due to a negative feedback loop: increased plasma [Ca2+] inhibits PTH and 1,25(OH)2D3, dampening further Ca2+ changes. Unlike Ca2+, the feedback loop of Mg2+ with 1,25(OH)2D3 is reinforcing, amplifying the impact of renal Mg2+ reabsorption changes.

Effect of different hypertensive stimuli

As described above, we adjusted selected parameters to investigate the model’s responses to different hypertensive stimuli: overactive RSNA, increased renin secretion, increased aldosterone secretion, increased vascular tone, or a combination of these stimuli (Table 2). Also, these parameters were chosen to yield MAP of approximately 120 mmHg, corresponding to an increase of 16%. Model predictions for each of these stimuli are shown in Fig 4.

thumbnail
Download:
Fig 4. Effect of hypertensive stimuli.

Fractional change from baseline (denoted by grey line at zero) of model variables (A) and Ca2+-Mg2+ fluxes (B) under five hypertensive stimuli: overactive RSNA (HTN-RSNA), increased renin secretion (HTN-Renin), increased aldosterone secretion (HTN-ALD), increased vascular tone (HTN-AA), and a combination of these stimuli (HTN-Combined). Bone to plasma and plasma to bone fluxes represent the exchange of Ca2+ and Mg2+ between plasma and the fast bone pool; bone resorption represents the release of Ca2+ and Mg2+ from the slow bone pool into plasma. MAP, mean arterial pressure; [ALD], aldosterone concentration; PRA, plasma renin activity; [AT1R-Ang II], plasma AT1R-bound Ang II concentration; RSNA, renal sympathetic nervous activity; RVR; renal vascular resistance; RBF, renal blood flow; GFR, glomerular filtration rate; , extracellular fluid volume; , total plasma sodium; [PTH], plasma PTH concentration; [1,25(OH)2D3,], plasma 1,25(OH)2D3 concentration; [Mg2+], plasma Mg2+ concentration; [Ca2+], plasma Ca2+ concentration.

https://doi.org/10.1371/journal.pone.0341800.g004

In the HTN-RSNA case, RSNA induces vasoconstriction and directly stimulates proximal tubule Na+ reabsorption. Taken in isolation, afferent arteriolar constriction would lower GFR. However, the resulting reduced Na+ flow at the macula densa inhibits the TGF signal and causes the afferent arteriole to slightly dilate. The higher MAP would also increase GFR. Together, these factors yield a GFR that is slightly higher than the normotensive values (Fig 4A). RSNA-induced hypertension does not cause any significant changes in plasma Ca2+, Mg2+, PTH, and 1,25(OH)2D3, levels or on any of Ca2+-Mg2+ fluxes.

In the HTN-Renin case (hyperreninemia), increased renin secretion elevates the level of AT1R-bound Ang II, which constricts both the afferent and efferent arterioles, but preferentially the latter. As a result, while renal blood flow was predicted to be almost unchanged from baseline, GFR was notably higher (22%; Fig 4A). The significantly increased aldosterone stimulates PTH secretion [40,41], thereby increasing plasma [PTH] by 33%. On one hand, this increased [PTH] inhibits proximal tubular Ca2+ and Mg2+ reabsorption, while on the other hand it increases Ca2+ and Mg2+ reabsorption along the thick ascending limb and distal tubule. Now, the majority of Ca2+ reabsorption occurs along the proximal tubule, while majority of Mg2+ reabsorption occurs along the thick ascending limb. Hence, combined with the higher filtered load, our model predicts a notably higher increase in urinary Ca2+ excretion than in urinary Mg2+ excretion (Fig 4B). Further, bone resorption increases by 13% under PTH, calcitriol, and AT1R-bound Ang II stimulation. Together, these factors do not cause any significant change in plasma Mg2+ and Ca2+ concentrations.

The HTN-ALD case simulates primary hyperaldosteronism, where the renin secretion rate remains normal, but there is hypersecretion of aldosterone, with a 30-fold increase above baseline.

Aldosterone secretion rate in primary aldosteronism is difficult to measure. However, we calculated the ratio of plasma aldosterone concentration (PAC) (ng/dL) to plasma renin activity (PRA) (pmol/L/min), which is commonly used in the diagnosis of primary aldosteronism. The proposed cut-off values for PAC/PRA ratio in the literature range from1.6 to 3.1 ng/dL per pmol/L/min [42]. We obtained a PAC/PRA ratio of 1.86 ng/dL per pmol/L/min with the predicted plasma aldosterone concentration and PRA values. The high levels of aldosterone cause the kidneys to retain Na+ and increase blood volume, which in turn signals the kidneys to decrease renin production. Our model predicts a 41% decrease in plasma renin activity and AT1R-bound Ang II (Fig 4A). The high aldosterone level also causes a 67% increase in PTH concentration (Fig 4A) [40,41]. This in turn inhibits proximal tubular Ca2+ and Mg2+ reabsorption, while increasing their reabsorption along the thick ascending limb. Consequently, our model predicts a 37% increase in urinary Ca2+ excretion [41,43] while urinary Mg2+ excretion is predicted to increase by 17% [44] (Fig 4B). Under the combined effect of increased PTH (67%), increased calcitriol (23%), and decreased AT1R-bound Ang II (41%), bone resorption increases by 3.8% [40,45,46] (Fig 4B). Together, these factors keep plasma Mg2+ and Ca2+ concentrations near the baseline values [41,44].

Afferent arteriole constriction in the HTN-AA case lowers GFR, whereas the increased MAP increases GFR. Under the influence of these two opposing factors GFR decreases by 8.5%. This in turn reduces proximal tubule Na+ and water reabsorption by a small amount. The increased Na+ delivery to the downstream segments increases Na+ reabsorption in the distal tubule and collecting duct. Hence, total plasma Na+ and extracellular fluid volume increase slightly. In addition, the reduced GFR lowers urinary Ca2+ and Mg2+ excretions.

The HTN-Combined case involves an overactive RSNA, an overactive RAAS, and increased vascular tone, with the strength of these stimuli chosen so that the predicted MAP is 120 mmHg (Table 2). The high aldosterone level increases [PTH] by 6.4%. However, it does not cause any notable change in any of the Ca2+ and Mg2+ fluxes.

In summary, the HTN-Renin, HTN-ALD, and HTN-AA cases exhibit significant changes in Ca2+ and Mg2+ fluxes from baseline. However, plasma Ca2+ and Mg2+ concentrations are predicted to remain within their respective physiological ranges for all hypertensive stimuli.

Effect of Mg2+, Ca2+, and vitamin D deficiency

Next, we separately simulated 70% dietary Mg2+ intake () restriction and 70% dietary Ca2+ intake () restriction. Vitamin D deficiency was simulated by limiting 25(OH)D (an immediate precursor of 1,25(OH)2D3) to 70%. Each of these restrictions was simulated for 1 month. Model predictions are shown in Fig 5.

thumbnail
Download:
Fig 5. Effect of Mg2+, Ca2+, and vitamin D3 deficiency.

(A) Fractional change from baseline (denoted by grey line at zero) of model variables under 70% dietary Mg2+ intake () restriction, 70% dietary Ca2+ intake () restriction, and 70% 25(OH)D (precursor of 1,25(OH)2D3) deficiency for 1 month. (B) Interplay between key variables that are affected by dietary Mg2+, dietary Ca2+, and 25(OH)D deficiency. Each variable is accompanied by their change over time for each of the three cases. Maroon bar plots, dietary Mg2+ deficiency; blue bar plots, dietary Ca2+ deficiency; green bar plots, 25(OH)D deficiency. The Y-axis range is [–0.7, 0.7]. MAP, mean arterial pressure; CO, cardiac output; TPR, total peripheral resistance; [ALD], aldosterone concentration; PRA, plasma renin activity; [AT1R-Ang II], AT1R-bound Ang II concentration; RSNA, renal sympathetic nervous activity; RVR; renal vascular resistance; GFR, glomerular filtration rate; Vecf, extracellular fluid volume; [PTH], plasma PTH concentration; [1,25(OH)2D3], plasma 1,25(OH)2D3 concentration; [Mg2+], plasma Mg2+ concentration; [Ca2+], plasma Ca2+ concentration; AR, arterial resistance.

https://doi.org/10.1371/journal.pone.0341800.g005

Our model predicts a 21% increase in MAP, from 103 mmHg to 125 mmHg, following 1 month of dietary Mg2+ restriction (Fig 5A). By contrast, 1 month of dietary Ca2+ restriction and 25(OH)D deficiency have comparatively lesser effect on MAP (increases to 119 mmHg and 114 mmHg, respectively). Now, why does Mg2+ deficiency have a higher effect on MAP compared to Ca2+ and 25(OH)D deficiency? Fig 5B shows the key variables and the interplay between them to answer the above question. Each variable is accompanied by their change over time for each of the three cases.

In the model MAP is calculated as the product of cardiac output and total peripheral resistance; the relative changes in these two factors determine the change in MAP. Dietary Mg2+ deficiency markedly lowers plasma [Mg2+], which in turn inhibits PTH secretion. Hence plasma [PTH] drops by 40%. This in turn partially removes the inhibitory effect of PTH on proximal tubule Na+ reabsorption. From Fig 5B, we see that RSNA (maroon bar plot) initially rises under the effect of lower plasma [Mg2+]. However, as MAP rises, its inhibitory effect brings down RSNA. Also, GFR (Fig 5B, maroon bar plot) does not change initially, but as MAP rises it increases renal blood flow and hence GFR. Thus, proximal tubule Na+ and water reabsorption is enhanced under the combined effect of increased GFR and removal of the inhibitory effect of PTH. Additionally, the lowered plasma [Mg2+] removes the inhibitory effect on aldosterone secretion causing an increase in plasma aldosterone levels. The high aldosterone levels enhance Na+ and water reabsorption in the distal tubule and collecting duct. Consequently, the extracellular fluid volume increases, which subsequently increases cardiac output by 12%. Now, the increased cardiac output increases the arterial resistance. This is because when more blood flows through any tissue of the body than is required by that tissue for its specific function, the local resistance to blood flow increases progressively to bring the blood flow back towards normal. On the other hand, the lower [PTH] decreases arterial resistance and lower [Mg2+] increases arterial resistance. Under the combined effect of these and cardiac output, arterial resistance increases which in turn increases the total peripheral resistance by 8.3%. Thus, dietary Mg2+ deficiency increases cardiac output and total peripheral resistance, which together cause a 21% increase in MAP. In fact, several observational studies, clinical trials, and meta-analyses have shown an inverse relationship between dietary Mg2+ intake and hypertension [47–51].

By contrast, dietary Ca2+ deficiency significantly increases plasma [PTH] due to the drop in plasma [Ca2+]. This reinforces the inhibitory effect of PTH on proximal tubule Na+ reabsorption. In addition, RSNA (Fig 5B, blue bar plot) decreases under the combined effect of lower plasma [Ca2+] and rising MAP. The increasing MAP also increases GFR (Fig 5B, blue bar plot). Furthermore, the lower plasma [Ca2+] removes the inhibitory effect on renin secretion; hence PRA increases, which in turn increases [AT1R-bound Ang II] (Fig 5B, blue bar plot). Together these factors slightly increase proximal tubule Na+ and water reabsorption. Additionally, the increased aldosterone (under the effect of increased [PTH] and [AT1R-bound Ang II]) increases Na+ and water reabsorption in the distal tubule and collecting duct. Hence, the extracellular fluid volume increases, which in turn increases cardiac output. On the other hand, the higher [AT1R-bound Ang II] and [PTH] increase arterial resistance and the lower [Ca2+] decreases arterial resistance. Together these factors increase total peripheral resistance by 15%. This increased resistance inhibits cardiac output. Consequently, cardiac output does not change from the baseline value. Thus, during dietary Ca2+ deficiency the 15% increase in MAP is primarily due to increased total peripheral resistance. Several observational studies, clinical trials, and meta-analyses have shown an inverse relationship between dietary Ca2+ intake and hypertension [52–54].

25(OH)D restriction results in calcitriol (1,25(OH)2D3) deficiency, which lowers intestinal absorption of Ca2+ and causes a drop in plasma [Ca2+]. This in turn increases PTH secretion. The decreased plasma [1,25(OH)2D3] also partially removes the inhibitory effect on PTH production, resulting in a higher rise in plasma [PTH] compared to the dietary Ca2+ deficiency case. In calcitriol deficiency, RAAS, renal Na+ and water reabsorption, and peripheral resistance undergo similar changes as in dietary Ca2+ deficiency, though the impact is lower. Consequently, MAP increases by only 11% [55–57].

Thus, our model predicts that the factor that causes Mg2+ deficiency to have a higher effect on MAP compared to Ca2+ and 25(OH)D deficiency is the increased cardiac output. During Mg2+ deficiency, changes in GFR, RSNA, [PTH], [AT1R-bound Ang II], and aldosterone significantly increase renal Na+ and water reabsorption, leading to a considerable increase in extracellular fluid volume and thus cardiac output. In contrast, in Ca2+ and 25(OH)D deficiency, changes in these factors cause only modest changes in extracellular fluid volume and hence cardiac output does not change significantly from baseline.

Primary hyperparathyroidism

Primary hyperparathyroidism was simulated by increasing the baseline PTH synthesis rate () by factors of 2, 3, 5, 7, and 10. Shown in Fig 6 are the predicted steady-state values of key model variables and fluxes. With these changes, the model predicts plasma [PTH] to increase by 70%, 130%, 237%, 334%, and 468%, respectively. As a result, plasma [1,25(OH)2D3] rises, which in turn greatly enhances intestinal Ca2+ absorption, while intestinal Mg2+ absorption increases slightly. This is because 1,25(OH)2D3 regulates 45% of intestinal Ca2+ absorption but only 12% of intestinal Mg2+ absorption. Further, bone resorption increases under the combined stimulation of PTH and 1,25(OH)2D3. Now, PTH inhibits proximal tubular Ca2+ and Mg2+ reabsorption, where the majority of the Ca2+ reabsorption occurs, while stimulating reabsorption along the thick ascending limb and distal tubule, where the majority of the Mg2+ reabsorption occurs. Hence, combined with the higher filtered load, our model predicts a notably higher increase in urinary Ca2+ excretion than in urinary Mg2+ excretion. Together these factors cause plasma [Ca2+] to increase by 7% (1.32 mM), 11% (1.37 mM), 15% (1.41 mM), 18% (1.45 mM), and 20% (1.48 mM), respectively, for 2-, 3-, 5-, 7-, and 10-fold increase in . Thus, in all five cases, plasma [Ca2+] is above its physiological range (1.1-1.3 mM) indicating hypercalcemia [58]. By contrast, the model predicts no change in plasma [Mg2+] [59].

thumbnail
Download:
Fig 6. Simulation results for primary hyperparathyroidism.

Fractional change from baseline (denoted by grey line at zero) of model variables (A, B) and Ca2+-Mg2+ fluxes (C) after increasing the baseline PTH synthesis rate () by factors of 2, 3, 5, 7, 10. [PTH], plasma PTH concentration; [1,25(OH)2D3], plasma 1,25(OH)2D3 concentration; [Mg2+], plasma Mg2+ concentration; [Ca2+], plasma Ca2+ concentration; MAP, mean arterial pressure; CO, cardiac output; TPR, total peripheral resistance; [ALD], aldosterone concentration; PRA, plasma renin activity; [AT1R-Ang II], AT1R-bound Ang II concentration; RSNA, renal sympathetic nervous activity; GFR, glomerular filtration rate; , extracellular fluid volume.

https://doi.org/10.1371/journal.pone.0341800.g006

Now let us analyze the effect on RAAS. The elevated plasma [Ca2+] inhibits renin secretion, whereas the elevated plasma [1,25(OH)2D3] increases renin secretion. Under their combined effect PRA increases significantly, which in turn increases AT1R-bound Ang II and aldosterone. The increased PTH and Ca2+ also increase aldosterone secretion. Thus, plasma aldosterone increases by 21%, 27%, 34%, 37%, and 42%, respectively, for 2-, 3-, 5-, 7-, and 10-fold increase in [32]. Renal Na+ and water reabsorption increases under the stimulation of AT1R-bound Ang II and aldosterone. An important point to note is that though PTH indirectly enhances Na+ reabsorption through the RAAS, it also directly inhibits proximal tubule Na+ reabsorption. Because of these two opposing factors, extracellular fluid volume and total plasma Na+ increase only slightly. Additionally, the higher [AT1R-bound Ang II] and [Ca2+] significantly increase arterial resistance and consequently total peripheral resistance. Thus, the increased extracellular fluid volume increases cardiac output, whereas the increased arterial resistance inhibits cardiac output and together these two factors keep cardiac output close to the baseline value. Consequently, MAP increases by 13% (116 mmHg), 14% (117 mmHg), 15.5% (119 mmHg), 16% (119.5 mmHg), and 17% (121 mmHg), respectively, for 2-, 3-, 5-, 7-, and 10-fold increase in . Thus, primary hyperparathyroidism causes hyperaldosteronism [32,60] and increases the risk of hypertension. In fact primary hyperparathyroidism has been associated with increased risk of hypertension, with a prevalence ranging from 40-65% and parathyroidectomy has resulted in substantial fall in both mean systolic and diastolic blood pressures [61–65]

Osteopenia and osteoporosis are known to be frequent complications of primary hyperparathyroidism [66–68]. Indeed our model predicts significant increase in bone resorption due to increased PTH and AT1R-bound Ang II.

Discussion

We have developed an integrated model of blood pressure regulation and Ca2+-Mg2+ homeostasis to gain insights into the complex interactions that govern these physiological processes. Our study highlights the bidirectional relationship between these two systems, where alterations in one can lead to significant changes in the other. Specifically, we demonstrated how dysregulation in Ca2+ and Mg2+ levels can affect blood pressure control, and how dysregulation in blood pressure control, such as in hypertension, can impact Ca2+ and Mg2+ homeostasis.

Hypertension has been associated with elevated plasma PTH [69], increased Ca2+ excretion [69,70], and reduced bone mineral density [71]. We simulated hypertension using different stimuli, namely, increased RSNA, increased renin secretion, increased aldosterone secretion, increased vascular tone, and a combination of all these stimuli. Simulation results (Fig 4) suggest that hypertensive states driven by elevated renin (HTN-Renin) and aldosterone (HTN-ALD) secretions significantly influence PTH, calcitriol, and the renal handling of Ca2+ and Mg2+. Notably, both conditions exhibit increased urinary excretion of Ca2+ and Mg2+, as well as elevated bone resorption (Fig 4). Primary hyperaldosteronism, which results from increased aldosterone secretion, has been associated with hyperparathyroidism [40,41] and increased urinary excretions of Ca2+ [41,43] and Mg2+ [44], although plasma Ca2+ and Mg2+ remain normal [41,44]. In fact, primary aldosteronism has been associated with nephrocalcinosis [72] and nephrolithiasis [73] caused by hypercalciuria. In addition, primary aldosteronism also causes bone loss and reduced bone mineral density [40,45,46]. Now, hyperreninemia, caused by increased renin secretion, has been associated with hyperaldosteronism [74,75]. Thus, the elevated aldosterone levels in hyperreninemia also increase PTH levels and hence urinary excretions of Ca2+ and Mg2+. Our model predicts a significantly higher increase in bone resorption rate in the HTN-Renin case compared to the HTN-ALD case (Fig 4). This is because increased renin secretion increases ATIR-bound Ang II, which increases the risk of osteoporosis. In fact, the use of angiotensin-converting enzyme (ACE) inhibitors have been associated with higher bone mineral density and reduced risk of fracture [76,77]. Despite these changes in urinary excretion and bone resorption rate, the model simulations indicate that plasma Ca2+ and Mg2+ concentrations remain relatively stable across all simulated hypertensive conditions (HTN-RSNA, HTN-Renin, HTN-ALD, HTN-AA, HTN-Combined) (Fig 4), suggesting that the body’s compensatory mechanisms effectively maintain mineral homeostasis even under pathological conditions.

Cross-sectional and longitudinal epidemiological studies have consistently reported an inverse relationship between dietary Mg2+ and blood pressure and/or hypertension [78–83]. Additionally, two large meta-analyses of randomized trials reported that Mg2+ supplementation significantly lowers blood pressure [49,50]. Hypomagnesemia has also been associated with pre-eclampsia [84–86], a pregnancy specific hypertensive disorder, and Mg2+ supplementation has been reported to reduce the risk of eclampsia in pregnant women by over 50% [87]. Together, these studies highlight the importance of Mg2+ homeostasis in blood pressure regulation. We conducted simulations to investigate the mechanisms responsible for increased mean arterial pressure during Mg2+ deficiency. Model simulations indicated that Mg2+ deficiency increased both cardiac output and total peripheral resistance (Fig 4). The increase in cardiac output was primarily due to decreased PTH and increased aldosterone, which increased renal Na+ and water reabsorption. Total peripheral resistance increased mainly due to increased cardiac output and removal of the inhibitory effect of Mg2+.

Several epidemiological studies have reported an inverse relationship between dietary Ca2+ intake and blood pressure and/or hypertension [52,53,78,79,82,85,88]. Simulation results are aligned with the observations from these studies. Unlike Mg2+, Ca2+ deficiency was predicted to increase the total peripheral resistance but did not change cardiac output (Fig 5). Additionally, our model predicted that dietary Mg2+ deficiency has a stronger effect on mean arterial pressure than dietary Ca2+ deficiency (Fig 5). In fact, two cross-sectional studies have reported dietary Mg2+ intake to have a stronger association with blood pressure compared to dietary Ca2+ intake [82,89]. Since calcitriol deficiency significantly lowers plasma [Ca2+], it has same effect as dietary Ca2+ deficiency on mean arterial pressure, i.e., an inverse association [55–57,90,91], although the impact is slightly lower.

Primary hyperparathyroidism has been associated with osteoporosis [66–68] and hypertension [61–65]. Our model predictions suggested that the elevated plasma PTH, Ca2+, and calcitriol are primarily responsible for these two disorders (Fig 5). These three factors overactivate the RAAS and increase vascular resistance, which in turn increases the mean arterial pressure. The elevated PTH, calcitriol, and AT1R-bound Ang II also promote bone loss (Fig 5).

In summary, we have developed a computational model representing the interplay between Ca2+ and Mg2+ homeostasis and blood pressure regulation in a male rat. The model was used to understand the underlying mechanisms involved in (i) regulating Ca2+ and Mg2+ balance during different hypertensive stimuli, (ii) blood pressure regulation during dietary Mg2+ deficiency, dietary Ca2+ deficiency, and vitamin D deficiency, and (iii) Ca2+, Mg2+, and blood pressure regulation during primary hyperparathyroidism.

Limitations of the study

The present model is based primarily on a male rat. However, there are many known sex differences in blood pressure regulation [29,33,92], and in the renal handling of Na+, Ca2+, and Mg2+ [93–96]. A worthwhile extension would be to develop sex-specific models for Ca2+, Mg2+, and blood pressure regulation under various physiological and pathophysiological conditions. Furthermore, there are significant interspecies differences between rat and human in terms of Ca2+, Mg2+, and blood pressure regulation, including intestinal Ca2+ and Mg2+ absorption, bone remodeling, and baseline hemodynamics. As such, the translation from rat to human is not straightforward. While qualitative feedback structure and directionality of hormonal effects may translate well, other more quantitative predictions such as time constants and gain values may not.

The actions of the transporters and channels along the nephron cell membranes that regulate Na+, Ca2+, Mg2+, and fluid balance are represented implicitly in our model. A possible extension of the model would be to explicitly model these transporters and channels as done in epithelial transport models [94,97,98]). The benefit of coupling individual nephron with whole kidney dynamics would be in simulating the administration of drugs that target these transporters. The exact action of the drug could then be simulated instead of inferred.

Dysregulated PTH and Ca2+ in hyper- and hypoparathyroidism exert important cardiovascular effects, including altered contractility, electrical instability, and ventricular remodeling. While our model captures their systemic interactions with mineral electrolyte and blood pressure regulation, their direct myocardial and electrophysiological actions are not explicitly included.

The present model does not include potassium (K+), which is a key electrolyte in blood pressure regulation. Higher K+ levels have been associated with lower blood pressure [99–101]. Its blood pressure-lowering effects stem from its capacity to induce vasodilation, a process mediated by vascular cell hyperpolarization [102]. Additionally, K+ influences blood pressure by increasing Na+ excretion, modulating baroreceptor sensitivity, reducing vasoconstrictive sensitivity to norepinephrine and angiotensin II, and increasing Na-K-ATPase activity [102]. A future extension of the model would be inclusion of K+ regulation [103,104] and its interaction with various components of blood pressure regulation.

Conclusion

This study introduces a comprehensive computational framework that unifies blood pressure regulation with Ca2+–Mg2+ homeostasis, enabling systematic exploration of how hormonal, renal, and vascular mechanisms jointly maintain cardiovascular and electrolyte stability. Through simulations of hypertension driven by distinct physiological triggers, mineral and vitamin D deficiencies, and primary hyperparathyroidism, the model reveals how perturbations in one system propagate through the other. The results highlight magnesium as a particularly influential regulator of blood pressure, show how RAAS activation can reshape calcium and magnesium fluxes without markedly altering plasma concentrations, and clarify how elevated PTH, calcitriol, and Ang II contribute to both hypertension and bone loss in hyperparathyroidism.

Overall, the model captures the multilayered feedbacks that couple mineral metabolism to cardiovascular control and provides mechanistic insights consistent with diverse experimental and clinical observations. By identifying pathways most sensitive to perturbation, this work offers a platform for hypothesis generation and for evaluating how dietary interventions, endocrine disorders, and therapeutic strategies might influence blood pressure and mineral balance. Future extensions incorporating sex differences, nephron-scale transporter modeling, and potassium regulation will further enhance the model’s predictive and translational potential.

Acknowledgments

The authors acknowledge the support of the University of Waterloo.

References

  1. 1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23. pmid:15652604
  2. 2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50. pmid:27502908
  3. 3. DiNicolantonio JJ, O’Keefe JH, Wilson W. Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Open Heart. 2018;5(1):e000668. pmid:29387426
  4. 4. Balk EM, Adam GP, Langberg VN, Earley A, Clark P, Ebeling PR, et al. Global dietary calcium intake among adults: a systematic review. Osteoporos Int. 2017;28(12):3315–24. pmid:29026938
  5. 5. Costello RB, Elin RJ, Rosanoff A, Wallace TC, Guerrero-Romero F, Hruby A, et al. Perspective: the case for an evidence-based reference interval for serum magnesium: the time has come. Adv Nutr. 2016;7(6):977–93. pmid:28140318
  6. 6. Yu Z, Li Y, Ba DM, Veldheer SJ, Sun L, Geng T. Trends in calcium intake among the US population: results from the NHANES 1999 –2018). Nutrients. 2024;16(5):726.
  7. 7. Bilezikian JP. Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2018;103(11):3993–4004. pmid:30060226
  8. 8. Vaidya A, Brown JM, Williams JS. The renin-angiotensin-aldosterone system and calcium-regulatory hormones. J Hum Hypertens. 2015;29(9):515–21. pmid:25631218
  9. 9. Zheng M-H, Li F-X-Z, Xu F, Lin X, Wang Y, Xu Q-S, et al. The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone. Front Endocrinol (Lausanne). 2020;11:539. pmid:32973674
  10. 10. Schutten JC, Joosten MM, de Borst MH, Bakker SJL. Magnesium and blood pressure: a physiology-based approach. Adv Chronic Kidney Dis. 2018;25(3):244–50. pmid:29793663
  11. 11. Atchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension. 2011;58(4):604–10. pmid:21825222
  12. 12. Atchison DK, Ortiz-Capisano MC, Beierwaltes WH. Acute activation of the calcium-sensing receptor inhibits plasma renin activity in vivo. Am J Physiol Regul Integr Comp Physiol. 2010;299(4):R1020-6. pmid:20660105
  13. 13. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170–9. pmid:18385669
  14. 14. Atchison DK, Harding P, Beierwaltes WH. Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity. Am J Physiol Renal Physiol. 2013;305(8):F1109-17. pmid:23926179
  15. 15. Schiebinger RJ, Braley LM, Menachery A, Williams GH. Calcium, a “third messenger” of cAMP-stimulated adrenal steroid secretion. Am J Physiol. 1985;248(1 Pt 1):E89-94. pmid:2981481
  16. 16. Atarashi K, Matsuoka H, Takagi M, Sugimoto T. Magnesium ion: a possible physiological regulator of aldosterone production. Life Sci. 1989;44(20):1483–9. pmid:2542710
  17. 17. Atarashi K, Takagi M, Matsuoka H, Sugimoto T. Effects of magnesium on changes in blood pressure and plasma aldosterone induced by angiotensin II. Am J Hypertens. 1990;3(6 Pt 1):488–90. pmid:2196065
  18. 18. Isales CM, Barrett PQ, Brines M, Bollag W, Rasmussen H. Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell. Endocrinology. 1991;129(1):489–95. pmid:1647306
  19. 19. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. American Journal of Physiology-Endocrinology and Metabolism. 2001;280(2):E209–13.
  20. 20. Kaufmann MA, Pargger H, Castelli I, Steiner LA, Drop LJ. Renal vascular responses to high and low ionized calcium: influence of norepinephrine in the isolated perfused rat kidney. J Trauma. 1996;40(1):110–5. pmid:8576971
  21. 21. Zhang J, Berra-Romani R, Sinnegger-Brauns MJ, Striessnig J, Blaustein MP, Matteson DR. Role of Cav1.2 L-type Ca2+ channels in vascular tone: effects of nifedipine and Mg2+. Am J Physiol Heart Circ Physiol. 2007;292(1):H415-25. pmid:16980345
  22. 22. Kawashima H. Parathyroid hormone causes a transient rise in intracellular ionized calcium in vascular smooth muscle cells. Biochem Biophys Res Commun. 1990;166(2):709–14. pmid:2154216
  23. 23. Lenzini L, Prisco S, Vanderriele PE, Lerco S, Torresan F, Maiolino G, et al. PTH modulation by aldosterone and angiotensin II is blunted in hyperaldosteronism and rescued by adrenalectomy. J Clin Endocrinol Metab. 2019;104(9):3726–34. pmid:30865228
  24. 24. Girardi AC, Titan SM, Malnic G, Rebouças NA. Chronic effect of parathyroid hormone on NHE3 expression in rat renal proximal tubules. Kidney Int. 2000;58(4):1623–31. pmid:11012896
  25. 25. Toka HR, Al-Romaih K, Koshy JM, DiBartolo S 3rd, Kos CH, Quinn SJ, et al. Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria. J Am Soc Nephrol. 2012;23(11):1879–90. pmid:22997254
  26. 26. Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, et al. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science. 1988;239(4835):57–61. pmid:2447647
  27. 27. Shimosawa T, Takano K, Ando K, Fujita T. Magnesium inhibits norepinephrine release by blocking N-type calcium channels at peripheral sympathetic nerve endings. Hypertension. 2004;44(6):897–902. pmid:15477382
  28. 28. Dutta P, Layton AT. Modeling calcium and magnesium balance: regulation by calciotropic hormones and adaptations under varying dietary intake. iScience. 2024;27(11):111077. pmid:39493879
  29. 29. Ahmed S, Layton AT. Sex-specific computational models for blood pressure regulation in the rat. Am J Physiol Renal Physiol. 2020;318(4):F888–900. pmid:32036698
  30. 30. Rude R, Manoogian C, Ehrlich L, DeRusso P, Ryzen E, Nadler J. Mechanisms of blood pressure regulation by magnesium in man. Magnesium. 1989;8(5–6):266–73.
  31. 31. Ureña P, Kong XF, Abou-Samra AB, Jüppner H, Kronenberg HM, Potts JT Jr, et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology. 1993;133(2):617–23. pmid:8393771
  32. 32. Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011;58(3):341–6. pmid:21825220
  33. 33. Leete J, Layton AT. Sex-specific long-term blood pressure regulation: modeling and analysis. Comput Biol Med. 2019;104:139–48. pmid:30472496
  34. 34. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22(7):2465–75. pmid:18256306
  35. 35. Richer C, Doussau MP, Giudicelli JF. Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats. Hypertension. 1983;5(3):312–20. pmid:6188693
  36. 36. Heeneman S, Smits JF, Leenders PJ, Schiffers PM, Daemen MJ. Effects of angiotensin II on cardiac function and peripheral vascular structure during compensated heart failure in the rat. Arterioscler Thromb Vasc Biol. 1997;17(10):1985–94. pmid:9351363
  37. 37. Prisby R, Menezes T, Campbell J. Vasodilation to PTH (1-84) in bone arteries is dependent upon the vascular endothelium and is mediated partially via VEGF signaling. Bone. 2013;54(1):68–75. pmid:23356989
  38. 38. Sgouralis I, Layton AT. Mathematical modeling of renal hemodynamics in physiology and pathophysiology. Math Biosci. 2015;264:8–20. pmid:25765886
  39. 39. Olgaard K, Lewin E, Bro S, Daugaard H, Egfjord M, Pless V. Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone. Miner Electrolyte Metab. 1994;20(5):309–14. pmid:7700220
  40. 40. Ceccoli L, Ronconi V, Giovannini L, Marcheggiani M, Turchi F, Boscaro M, et al. Bone health and aldosterone excess. Osteoporos Int. 2013;24(11):2801–7. pmid:23695421
  41. 41. Fortina F, Bellosta S. Hyperparathyroidism secondary to hyperaldosteronism. High blood pressure and cardiovascular prevention. 2010;17(1):27–30.
  42. 42. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. pmid:26934393
  43. 43. Rastegar A, Agus Z, Connor TB, Goldberg M. Renal handling of calcium and phosphate during mineralocorticoid “escape” in man. Kidney Int. 1972;2(5):279–86. pmid:4670906
  44. 44. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962;22:1187–92. pmid:13964048
  45. 45. Shi S, Lu C, Tian H, Ren Y, Chen T. Primary aldosteronism and bone metabolism: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:574151. pmid:33101208
  46. 46. Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, et al. Bone involvement in aldosteronism. J Bone Miner Res. 2012;27(10):2217–22. pmid:22589146
  47. 47. Han H, Fang X, Wei X, Liu Y, Jin Z, Chen Q, et al. Dose-response relationship between dietary magnesium intake, serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis of prospective cohort studies. Nutr J. 2017;16(1):26. pmid:28476161
  48. 48. Peacock JM, Folsom AR, Arnett DK, Eckfeldt JH, Szklo M. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1999;9(3):159–65. pmid:10192647
  49. 49. Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr. 2012;66(4):411–8. pmid:22318649
  50. 50. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016;68(2):324–33. pmid:27402922
  51. 51. Alharran AM, Alzayed MM, Jamilian P, Prabahar K, Kamal AH, Alotaibi MN, et al. Impact of magnesium supplementation on blood pressure: an umbrella meta-analysis of randomized controlled trials. Curr Ther Res Clin Exp. 2024;101:100755. pmid:39280209
  52. 52. van Mierlo LAJ, Arends LR, Streppel MT, Zeegers MPA, Kok FJ, Grobbee DE, et al. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2006;20(8):571–80. pmid:16673011
  53. 53. Cormick G, Ciapponi A, Cafferata ML, Cormick MS, Belizán JM. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2021;8(8):CD010037. pmid:34693985
  54. 54. Villa-Etchegoyen C, Lombarte M, Matamoros N, Belizán JM, Cormick G. Mechanisms involved in the relationship between low calcium intake and high blood pressure. Nutrients. 2019;11(5):1112. pmid:31109099
  55. 55. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159–65. pmid:17563024
  56. 56. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009;6(10):621–30. pmid:19687790
  57. 57. Almirall J, Vaqueiro M, Baré ML, Anton E. Association of low serum 25-hydroxyvitamin D levels and high arterial blood pressure in the elderly. Nephrol Dial Transplant. 2010;25(2):503–9. pmid:19749143
  58. 58. Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;2:16033. pmid:27194212
  59. 59. King RG, Stanbury SW. Magnesium metabolism in primary hyperparathyroidism. Clin Sci. 1970;39(2):281–303. pmid:5473585
  60. 60. Brunaud L, Germain A, Zarnegar R, Rancier M, Alrasheedi S, Caillard C, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146(6):1035–41. pmid:19958930
  61. 61. Broulik PD, Brouliková A, Adámek S, Libanský P, Tvrdo ň J, Broulikova K, et al. Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int J Endocrinol. 2011;2011:309068. pmid:21403888
  62. 62. Schiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence?. Int J Endocrinol. 2011;2011:974647. pmid:21423544
  63. 63. Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery. 2009;146(6):1042–7. pmid:19958931
  64. 64. Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005;19(11):901–6. pmid:16034450
  65. 65. Kalla A, Krishnamoorthy P, Gopalakrishnan A, Garg J, Patel NC, Figueredo VM. Primary hyperparathyroidism predicts hypertension: results from the National Inpatient Sample. Int J Cardiol. 2017;227:335–7. pmid:27847154
  66. 66. Cormier C, Souberbielle J-C, Kahan A. Primary hyperparathyroidism and osteoporosis in 2004 . Joint Bone Spine. 2004;71(3):183–9. pmid:15182788
  67. 67. Lewiecki EM, Miller PD. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J Clin Densitom. 2013;16(1):28–32. pmid:23374738
  68. 68. Kanis JA, Harvey NC, Liu E, Vandenput L, Lorentzon M, McCloskey EV, et al. Primary hyperparathyroidism and fracture probability. Osteoporos Int. 2023;34(3):489–99. pmid:36525071
  69. 69. Strazzullo P, Nunziata V, Cirillo M, Giannattasio R, Ferrara LA, Mattioli PL, et al. Abnormalities of calcium metabolism in essential hypertension. Clin Sci (Lond). 1983;65(2):137–41. pmid:6305548
  70. 70. Young EW, Morris CD, McCarron DA. Urinary calcium excretion in essential hypertension. J Lab Clin Med. 1992;120(4):624–32. pmid:1402338
  71. 71. Ye Z, Lu H, Liu P. Association between essential hypertension and bone mineral density: a systematic review and meta-analysis. Oncotarget. 2017;8(40):68916–27. pmid:28978167
  72. 72. Yang CW, Kim SY, Kim YS, Koo WS, Choi EJ, Chang YS, et al. Nephrocalcinosis associated with primary aldosteronism. Nephron. 1994;68(4):507–8. pmid:7870238
  73. 73. Shey J, Cameron MA, Sakhaee K, Moe OW. Recurrent calcium nephrolithiasis associated with primary aldosteronism. Am J Kidney Dis. 2004;44(1):e7-12. pmid:15211456
  74. 74. Trnka P, Orellana L, Walsh M, Pool L, Borzi P. Reninoma: an uncommon cause of Renin-mediated hypertension. Front Pediatr. 2014;2:89. pmid:25177679
  75. 75. Schambelan M, Howes EL Jr, Noakes CA, Biglieri EG. Role of renin and aldosterone in hypertension due to a renin-secreting tumor. Am J Med. 1973;55(1):86–92. pmid:4715934
  76. 76. Lynn H, Kwok T, Wong SYS, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone. 2006;38(4):584–8. pmid:16257280
  77. 77. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006;24(3):581–9. pmid:16467662
  78. 78. Cheteu Wabo TM, Wu X, Sun C, Boah M, Ngo Nkondjock VR, Kosgey Cheruiyot J, et al. Association of dietary calcium, magnesium, sodium, and potassium intake and hypertension: a study on an 8-year dietary intake data from the National Health and Nutrition Examination Survey. Nutr Res Pract. 2022;16(1):74–93. pmid:35116129
  79. 79. Beydoun MA, Gary TL, Caballero BH, Lawrence RS, Cheskin LJ, Wang Y. Ethnic differences in dairy and related nutrient consumption among US adults and their association with obesity, central obesity, and the metabolic syndrome. Am J Clin Nutr. 2008;87(6):1914–25. pmid:18541585
  80. 80. Ford ES, Li C, McGuire LC, Mokdad AH, Liu S. Intake of dietary magnesium and the prevalence of the metabolic syndrome among U.S. adults. Obesity (Silver Spring). 2007;15(5):1139–46. pmid:17495189
  81. 81. Tan M-Y, Mo C-Y, Zhao Q. The Association between Magnesium Depletion Score, Hypertension in US Adults: Evidence from the National Health and Nutrition Examination Survey 2007 -2018). Biol Trace Elem Res. 2024;202(10):4418–30. pmid:38147232
  82. 82. Van Leer EM, Seidell JC, Kromhout D. Dietary calcium, potassium, magnesium and blood pressure in the Netherlands. Int J Epidemiol. 1995;24(6):1117–23. pmid:8824852
  83. 83. Bain LKM, Myint PK, Jennings A, Lentjes MAH, Luben RN, Khaw K-T, et al. The relationship between dietary magnesium intake, stroke and its major risk factors, blood pressure and cholesterol, in the EPIC-Norfolk cohort. Int J Cardiol. 2015;196:108–14. pmid:26082204
  84. 84. Enaruna NO, Ande A, Okpere EE. Clinical significance of low serum magnesium in pregnant women attending the University of Benin Teaching Hospital. Niger J Clin Pract. 2013;16(4):448–53. pmid:23974737
  85. 85. Kanagal DV, Rajesh A, Rao K, Devi UH, Shetty H, Kumari S, et al. Levels of serum calcium and magnesium in pre-eclamptic and normal pregnancy: a study from coastal India. J Clin Diagn Res. 2014;8(7):OC01-4. pmid:25177604
  86. 86. Jafrin W, Mia AR, Chakraborty PK, Hoque MR, Paul UK, Shaha KR, et al. An evaluation of serum magnesium status in pre-eclampsia compared to the normal pregnancy. Mymensingh Med J. 2014;23(4):649–53. pmid:25481580
  87. 87. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–90. pmid:12057549
  88. 88. Witteman JC, Willett WC, Stampfer MJ, Colditz GA, Sacks FM, Speizer FE, et al. A prospective study of nutritional factors and hypertension among US women. Circulation. 1989;80(5):1320–7. pmid:2805268
  89. 89. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr. 1987;45(2):469–75. pmid:3812346
  90. 90. Bricio-Barrios JA Rd, Palacios-Fonseca AJ MSc, Del Toro-Equihua M, Sanchez-Ramirez CA. Effect of calcitriol supplementation on blood pressure in older adults. J Nutr Gerontol Geriatr. 2016;35(4):243–52. pmid:27897610
  91. 91. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997;30(5):1289–94. pmid:9369290
  92. 92. Ahmed S, Hu R, Leete J, Layton AT. Understanding sex differences in long-term blood pressure regulation: insights from experimental studies and computational modeling. Am J Physiol Heart Circ Physiol. 2019;316(5):H1113–23. pmid:30875261
  93. 93. Veiras LC, Girardi ACC, Curry J, Pei L, Ralph DL, Tran A, et al. Sexual dimorphic pattern of renal transporters and electrolyte homeostasis. J Am Soc Nephrol. 2017;28(12):3504–17. pmid:28774999
  94. 94. Dutta P, Hakimi S, Layton AT. How the kidney regulates magnesium: a modelling study. R Soc Open Sci. 2024;11(3):231484. pmid:38511086
  95. 95. Hakimi S, Dutta P, Layton AT. Coupling of renal sodium and calcium transport: a modeling analysis of transporter inhibition and sex differences. Am J Physiol Renal Physiol. 2023;325(5):F536–51. pmid:37615047
  96. 96. Hu R, McDonough AA, Layton AT. Sex differences in solute and water handling in the human kidney: modeling and functional implications. iScience. 2021;24(6).
  97. 97. Layton AT, Edwards A. Mathematical modeling in renal physiology. vol. 862. Springer; 2014.
    • 98. Layton AT, Laghmani K, Vallon V, Edwards A. Solute transport and oxygen consumption along the nephrons: effects of Na+ transport inhibitors. Am J Physiol Renal Physiol. 2016;311(6):F1217–29. pmid:27707706
    • 99. Filippini T, Violi F, D’Amico R, Vinceti M. The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis. Int J Cardiol. 2017;230:127–35. pmid:28024910
    • 100. Chan Q, Wren GM, Lau C-HE, Ebbels TMD, Gibson R, Loo RL, et al. Blood pressure interactions with the DASH dietary pattern, sodium, and potassium: The International Study of Macro-/Micronutrients and Blood Pressure (INTERMAP). Am J Clin Nutr. 2022;116(1):216–29. pmid:35285859
    • 101. Yu J, Thout SR, Li Q, Tian M, Marklund M, Arnott C, et al. Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. Am J Clin Nutr. 2021;114(1):185–93. pmid:33782684
    • 102. Haddy FJ, Vanhoutte PM, Feletou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol Regul Integr Comp Physiol. 2006;290(3):R546-52. pmid:16467502
    • 103. Stadt MM, Leete J, Devinyak S, Layton AT. A mathematical model of potassium homeostasis: effect of feedforward and feedback controls. PLoS Comput Biol. 2022;18(12):e1010607. pmid:36538563
    • 104. Stadt M, Layton AT. Modulation of blood pressure by dietary potassium and sodium: sex differences and modeling analysis. Am J Physiol Renal Physiol. 2025;328(3):F406–17. pmid:39447116